Last reviewed · How we verify

ladostigil hemitartrate

Avraham Pharmaceuticals Ltd · Phase 2 active Small molecule

ladostigil hemitartrate is a Small molecule drug developed by Avraham Pharmaceuticals Ltd. It is currently in Phase 2 development. Also known as: ladostigil, Ladostigil capsules.

At a glance

Generic nameladostigil hemitartrate
Also known asladostigil, Ladostigil capsules
SponsorAvraham Pharmaceuticals Ltd
ModalitySmall molecule
PhasePhase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about ladostigil hemitartrate

What is ladostigil hemitartrate?

ladostigil hemitartrate is a Small molecule drug developed by Avraham Pharmaceuticals Ltd.

Who makes ladostigil hemitartrate?

ladostigil hemitartrate is developed by Avraham Pharmaceuticals Ltd (see full Avraham Pharmaceuticals Ltd pipeline at /company/avraham-pharmaceuticals-ltd).

Is ladostigil hemitartrate also known as anything else?

ladostigil hemitartrate is also known as ladostigil, Ladostigil capsules.

What development phase is ladostigil hemitartrate in?

ladostigil hemitartrate is in Phase 2.

Related